Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs

Autor(es)

Reimao, Juliana Quero ^[1] ; Tempone, Andre Gustavo ^[1]

Afiliação do(s) autor(es)

^[1] Adolfo Lutz Inst, Dept Parasitol, BR-01246000 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Memórias do Instituto Oswaldo Cruz; v. 106, n. 8, p. 1032-1038, DEC 2011.
• Citações Web of Science: 8

Resumo

The need for drug combinations to treat visceral leishmaniasis (VL) arose because of resistance to antimonials, the toxicity of current treatments and the length of the course of therapy. Calcium channel blockers (CCBs) have shown anti-leishmanial activity; therefore their use in combination with standard drugs could provide new alternatives for the treatment of VL. In this work, in vitro isobolograms of Leishmania (Leishmania) chagasi using promastigotes or intracellular amastigotes were utilised to identify the interactions between five CCBs and the standard drugs pentamidine, amphotericin B and glucantime. The drug interactions were assessed with a fixed ratio isobologram method and the fractional inhibitory concentrations (FICs), sum of FICs (Sigma FICs) and the overall mean Sigma FIC were calculated for each combination. Graphical isobologram analysis showed that the combination of nimodipine and glucantime was the most promising in amastigotes with an overall mean Sigma FIC value of 0.79. Interactions between CCBs and the anti-leishmanial drugs were classified as indifferent according to the overall mean Sigma FIC and the isobologram graphic analysis. (AU)

• Processo FAPESP: 08/11434-3 - Combinações terapêuticas na leishmaniose visceral: o potencial anti-Leishmania de bloqueadores de canais de cálcio
• Beneficiário: Juliana Quero Reimão Dalla Zanna
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 08/09260-7 - Combinações terapêuticas na leishmaniose visceral: o potencial anti-leishmania de bloqueadores de canais de cálcio e o uso de nanoformulações lipossomais
• Beneficiário: André Gustavo Tempone Cardoso
• Linha de fomento: Auxílio à Pesquisa - Regular